The performance of companies tied to Sildenafil's legacy presents a complex investment scenario . While the initial boom generated substantial gains, generic competition have significantly impacted revenue. Investing in connected pharmaceutical businesses now requires a discerning assessment of proprietary protection , evolving medical trends , and